Local newcomer aims to break into Nordic generic market dominated by multinationals
This article was originally published in Scrip
Executive Summary
A company that has set itself the target of becoming the fifth largest generics player in the Nordic region by 2015 has launched its first two products. Norwegian firm Navamedic, which last year signed a deal with the major generics producer Aspen of South Africa giving it exclusive rights to sell Aspen products in the Nordic and Benelux markets, has launched the immunosuppressant mycophenolate mofetil in Sweden, Denmark and Finland, and the antipsychotic olanzapine in Finland and the Netherlands.